Anti-PRKAB1 Antibody, clone 2M11 ZooMAb^® Rabbit Monoclonal

KLH-conjugated linear peptide corresponding to 24 amino acids from the N-terminal region of human PRKAB1.

Quality Control Testing

Evaluated by Western Blotting in lysate from HeLa cells.

Western Blotting Analysis: A 1:1,000 dilution of this antibody detected PRKAB1 in lysate from HeLa cells.

Tested Applications

Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected PRKAB1 in lysates from K-562 cells and mouse kidney tissue.

Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected PRKAB1 in human kidney tissue sections.

Affinity Binding Assay: A representative lot of this antibody bound PRKAB1 peptide with at least ten thousand-fold (10,000X) higher affinity than with non-specific control peptide.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Clone 2M1 is a ZooMAb^® recombinant rabbit monoclonal antibody that specifically detects PRKAB1. It targets an epitope within 24 amino acids from the N-terminal region.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

5′-AMP-activated protein kinase subunit beta-1 (UniProt: Q9Y478; also known as AMPK subunit beta-1, AMPKb) is encoded by the PRKAB1 (also known as AMPK) gene (Gene ID: 5564) in human.The protein encoded by this gene is a regulatory subunit of the AMP-activated protein kinase (AMPK). AMPK is a heterotrimer consisting of an alpha catalytic subunit, and non-catalytic beta and gamma subunits. AMPK is an important energy-sensing enzyme that monitors cellular energy status. In response to cellular metabolic stresses, AMPK is activated, and thus phosphorylates and inactivates acetyl-CoA carboxylase (ACC) and beta-hydroxy beta-methylglutaryl-CoA reductase (HMGCR), key enzymes involved in regulating de novo biosynthesis of fatty acid and cholesterol. This subunit may be a positive regulator of AMPK activity. PRKAB1 is widely expressed in various tissues, including skeletal muscle, liver, and adipose tissue, indicating its essential role in metabolic regulation. It is primarily localized in the cytoplasm, with additional presence in the nucleoplasm and nucleus. The myristoylation and phosphorylation of this subunit have been shown to affect the enzyme activity and cellular localization of AMPK. This subunit may also serve as an adaptor molecule mediating the association of the AMPK complex. PRKAB1 is phosphorylated when associated with the catalytic subunit (PRKAA1 or PRKAA2). It is also phosphorylated by ULK1, which negatively regulates AMPK activity and suggests the existence of a regulatory feedback loop between ULK1 and AMPK. Dysregulation of PRKAB1 has been linked to several diseases, including type 2 diabetes and various cancers, where altered AMPK signaling can lead to metabolic dysfunction and tumorigenesis. Recent studies have demonstrated association of PRKAB1 mRNA expression with occurrence of coronary artery disease in type 2 diabetes, highlighting its potential as a biomarker and therapeutic target. This ZooMAb^® recombinant monoclonal antibody, generated by our proprietary technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Rahimi, E., et al. (2020). Diabetes. Res Clin Pract. 5(151):39-45).

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany